- REPORT SUMMARY
- TABLE OF CONTENTS
-
The report details the trend, potential and market size of Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs market, and analyzes the current situation and prospects of the market from both qualitative and quantitative aspects, which can be roughly divided into three parts.
The first part (Chapter1-7) mainly covers the qualitative analysis of Kidney Cancer and Renal Cell Carcinoma (RCC) Drugsmarket, defines the market attractiveness level of Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs market through Porter's Five Forces Analysis, and summarizes the different factors in the overall environment through PEST analysis. Understand the distribution of industrial chain value in each link of industrial chain through the analysis of industrial chain structure. Thus estimate the market space of each link.
The second part (Chapter8-12), based on the segmentation of Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs industry, describes the types of Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs market, the applications of major players and the market size, and deeply analyzes the current situation of the global Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs market and the development prospects and opportunities of Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs industry.
The third part (Chapter14-15) includes the market positions of the major players and information on the market participants, which will help you gain a comprehensive understanding of the current competitive situation and potential growth opportunities in the market.
As COVID-19 continues to impact the global economy in 2022, the report also considers the short - and long-term impacts of COVID-19 on the global Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs market in Chapter 13.
By Player:
Active Biotech Ab
Roche Holding AG
Bayer AG
Amgen
Cipla Limited
Pfizer
By Type:
Afinitor (Everolimus)
Avastin (Bevacizumab)
Nexavar (Sorafenib)
Proleukin (Aldesleukin)
Torisel (Temsirolimus)
Sutent (Sunitinib)
Votrient (Pazopanib)
By End-User:
Hospitals
Clinic
Others
By Geography:
-
United States
-
Europe
-
China
-
Japan
-
India
-
South Korea
TABLE OF CONTENT
1 Introduction
-
1.1 Market Definition
-
1.2 Market Segment Analysis
-
1.3 Market Size 2022
-
1.4 Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Market Outlook: Forecast for 2022 - 2028
-
1.5 Pricing Analysis
2 Executive Summary
3 Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Market Lineage Outlook
-
3.1 Parent Market Outlook
-
3.2 Related/Ancillary Market Outlook
-
3.3 Penetration & Growth Prospect Mapping, 2022
4 Market Analysis Tools: Porter's Five Forces
-
4.1 Supplier Power
-
4.2 Buyer Power
-
4.3 Substitution Threat
-
4.4 Threat of New Entrants
-
4.5 Competitive Rivalry
5 Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Industry Analysis - PEST (Political & Legal, Economic, Social, and Technological)
-
5.1 Political/Legal Landscape
-
5.2 Economic Landscape
-
5.3 Social Landscape
-
5.4 Technology Landscape
6 Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Market - Value Chain Analysis
-
6.1 Industry's Value Chain Analysis
-
6.2 Product Life Cycle
-
6.3 User Perspective Analysis
7 Region and Country-wise Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Market Analysis and Outlook to 2022
-
7.1 Global Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Consumption (2017-2022)
-
7.2 United States Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Consumption (2017-2022)
-
7.3 Europe Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Consumption (2017-2022)
-
7.4 China Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Consumption (2017-2022)
-
7.5 Japan Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Consumption (2017-2022)
-
7.6 India Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Consumption (2017-2022)
-
7.7 South Korea Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Consumption (2017-2022)
8 Region and Country-wise Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Market Analysis and Outlook to 2028
-
8.1 Global Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Consumption Forecast (2022-2028)
-
8.2 United States Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Consumption Forecast (2022-2028)
-
8.3 Europe Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Consumption Forecast (2022-2028)
-
8.4 China Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Consumption Forecast (2022-2028)
-
8.5 Japan Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Consumption Forecast (2022-2028)
-
8.6 India Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Consumption Forecast (2022-2028)
-
8.7 South Korea Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Consumption Forecast (2022-2028)
9 Global Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Market Outlook by Types and Applications to 2022
-
9.1 Global Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Consumption and Growth Rate by Type (2017-2022)
-
9.1.1 Global Afinitor (Everolimus) Consumption and Growth Rate (2017-2022)
-
9.1.2 Global Avastin (Bevacizumab) Consumption and Growth Rate (2017-2022)
-
9.1.3 Global Nexavar (Sorafenib) Consumption and Growth Rate (2017-2022)
-
9.1.4 Global Proleukin (Aldesleukin) Consumption and Growth Rate (2017-2022)
-
9.1.5 Global Torisel (Temsirolimus) Consumption and Growth Rate (2017-2022)
-
9.1.6 Global Sutent (Sunitinib) Consumption and Growth Rate (2017-2022)
-
9.1.7 Global Votrient (Pazopanib) Consumption and Growth Rate (2017-2022)
-
9.2 Global Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Consumption and Growth Rate by Application (2017-2022)
-
9.2.1 Global Hospitals Consumption and Growth Rate (2017-2022)
-
9.2.2 Global Clinic Consumption and Growth Rate (2017-2022)
-
9.2.3 Global Others Consumption and Growth Rate (2017-2022)
10 Global Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Market Outlook by Types and Applications to 2028
-
10.1 Global Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Consumption Forecast and Growth Rate by Type (2022-2028)
-
10.1.1 Global Afinitor (Everolimus) Consumption Forecast and Growth Rate (2022-2028)
-
10.1.2 Global Avastin (Bevacizumab) Consumption Forecast and Growth Rate (2022-2028)
-
10.1.3 Global Nexavar (Sorafenib) Consumption Forecast and Growth Rate (2022-2028)
-
10.1.4 Global Proleukin (Aldesleukin) Consumption Forecast and Growth Rate (2022-2028)
-
10.1.5 Global Torisel (Temsirolimus) Consumption Forecast and Growth Rate (2022-2028)
-
10.1.6 Global Sutent (Sunitinib) Consumption Forecast and Growth Rate (2022-2028)
-
10.1.7 Global Votrient (Pazopanib) Consumption Forecast and Growth Rate (2022-2028)
-
10.2 Global Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Consumption Forecast and Growth Rate by Application (2022-2028)
-
10.2.1 Global Hospitals Consumption Forecast and Growth Rate (2022-2028)
-
10.2.2 Global Clinic Consumption Forecast and Growth Rate (2022-2028)
-
10.2.3 Global Others Consumption Forecast and Growth Rate (2022-2028)
11 Global Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Import and Export Analysis (Top 5 Countries)
-
11.1 Global Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Import by Region (Top 5 Countries) (2017-2028)
-
11.2 Global Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Export by Region (Top 5 Countries) (2017-2028)
12 Coronavirus Disease (COVID-19) Impact
-
12.1 Industry Impact Analysis
-
12.2 Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Market Outlook to 2028 - COVID-19 Affected Forecasts
13 Competition Matrix
-
13.1 Target Markets
-
13.2 Comprehensive Analysis of Products in Competitive Markets
14 Global Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Market Competitive Analysis
-
14.1 Active Biotech Ab
-
14.1.1 Active Biotech Ab Company Details
-
14.1.2 Active Biotech Ab Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Sales, Price, Value and Gross Profit (2017-2022)
-
14.1.3 Active Biotech Ab Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Product and Service
-
14.2 Roche Holding AG
-
14.2.1 Roche Holding AG Company Details
-
14.2.2 Roche Holding AG Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Sales, Price, Value and Gross Profit (2017-2022)
-
14.2.3 Roche Holding AG Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Product and Service
-
14.3 Bayer AG
-
14.3.1 Bayer AG Company Details
-
14.3.2 Bayer AG Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Sales, Price, Value and Gross Profit (2017-2022)
-
14.3.3 Bayer AG Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Product and Service
-
14.4 Amgen
-
14.4.1 Amgen Company Details
-
14.4.2 Amgen Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Sales, Price, Value and Gross Profit (2017-2022)
-
14.4.3 Amgen Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Product and Service
-
14.5 Cipla Limited
-
14.5.1 Cipla Limited Company Details
-
14.5.2 Cipla Limited Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Sales, Price, Value and Gross Profit (2017-2022)
-
14.5.3 Cipla Limited Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Product and Service
-
14.6 Pfizer
-
14.6.1 Pfizer Company Details
-
14.6.2 Pfizer Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Sales, Price, Value and Gross Profit (2017-2022)
-
14.6.3 Pfizer Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Product and Service
15 Appendix
TABLE OF CHARTS
-
Table Definition of Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs
-
Figure Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Picture
-
Table Global Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Market Size and Forecast 2022 - 2028 (USD million)
-
Figure Global Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Market Size and Forecast 2022 - 2028 (USD million)
-
Figure Global Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Market: Year-over-year Growth 2022 - 2028 (%)
-
Table Parent Market Analysis
-
Figure Parent Market Price
-
Table Related/Ancillary Market Outlook Analysis
-
Table Supplier Power Analysis
-
Table Buyer Power Analysis
-
Table Substitution Threat Analysis
-
Table Threat of New Entrants Analysis
-
Table Competitive Rivalry Analysis
-
Figure Global Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Consumption by Country (2017-2022)
-
Figure United States Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Consumption and Growth Rate (2017-2022)
-
Table Europe Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Consumption and Growth Rate (2017-2022)
-
Figure China Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Consumption and Growth Rate (2017-2022)
-
Figure Japan Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Consumption and Growth Rate (2017-2022)
-
Figure India Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Consumption and Growth Rate (2017-2022)
-
Figure South Korea Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Consumption and Growth Rate (2017-2022)
-
Figure Global Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Consumption Forecast by Country (2022-2028)
-
Figure United States Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Consumption Forecast and Growth Rate (2022-2028)
-
Table Europe Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Consumption Forecast and Growth Rate (2022-2028)
-
Figure China Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Consumption Forecast and Growth Rate (2022-2028)
-
Figure Japan Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Consumption Forecast and Growth Rate (2022-2028)
-
Figure India Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Consumption Forecast and Growth Rate (2022-2028)
-
Figure South Korea Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Consumption Forecast and Growth Rate (2022-2028)
-
Figure Global Afinitor (Everolimus) Consumption and Growth Rate (2017-2022)
-
Figure Global Avastin (Bevacizumab) Consumption and Growth Rate (2017-2022)
-
Figure Global Nexavar (Sorafenib) Consumption and Growth Rate (2017-2022)
-
Figure Global Proleukin (Aldesleukin) Consumption and Growth Rate (2017-2022)
-
Figure Global Torisel (Temsirolimus) Consumption and Growth Rate (2017-2022)
-
Figure Global Sutent (Sunitinib) Consumption and Growth Rate (2017-2022)
-
Figure Global Votrient (Pazopanib) Consumption and Growth Rate (2017-2022)
-
Figure Global Hospitals Consumption and Growth Rate (2017-2022)
-
Figure Global Clinic Consumption and Growth Rate (2017-2022)
-
Figure Global Others Consumption and Growth Rate (2017-2022)
-
Figure Global Afinitor (Everolimus) Consumption Forecast and Growth Rate (2022-2028)
-
Figure Global Avastin (Bevacizumab) Consumption Forecast and Growth Rate (2022-2028)
-
Figure Global Nexavar (Sorafenib) Consumption Forecast and Growth Rate (2022-2028)
-
Figure Global Proleukin (Aldesleukin) Consumption Forecast and Growth Rate (2022-2028)
-
Figure Global Torisel (Temsirolimus) Consumption Forecast and Growth Rate (2022-2028)
-
Figure Global Sutent (Sunitinib) Consumption Forecast and Growth Rate (2022-2028)
-
Figure Global Votrient (Pazopanib) Consumption Forecast and Growth Rate (2022-2028)
-
Figure Global Hospitals Consumption Forecast and Growth Rate (2022-2028)
-
Figure Global Clinic Consumption Forecast and Growth Rate (2022-2028)
-
Figure Global Others Consumption Forecast and Growth Rate (2022-2028)
-
Table Global Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Import by Region (Top 5 Countries) (2017-2028)
-
Table Global Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Export by Region (Top 5 Countries) (2017-2028)
-
Table Active Biotech Ab (Foundation Year, Company Profile and etc.)
-
Table Active Biotech Ab Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Sales, Price, Value and Gross Profit (2017-2022)
-
Table Active Biotech Ab Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Product and Service
-
Table Roche Holding AG (Foundation Year, Company Profile and etc.)
-
Table Roche Holding AG Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Sales, Price, Value and Gross Profit (2017-2022)
-
Table Roche Holding AG Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Product and Service
-
Table Bayer AG (Foundation Year, Company Profile and etc.)
-
Table Bayer AG Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Sales, Price, Value and Gross Profit (2017-2022)
-
Table Bayer AG Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Product and Service
-
Table Amgen (Foundation Year, Company Profile and etc.)
-
Table Amgen Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Sales, Price, Value and Gross Profit (2017-2022)
-
Table Amgen Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Product and Service
-
Table Cipla Limited (Foundation Year, Company Profile and etc.)
-
Table Cipla Limited Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Sales, Price, Value and Gross Profit (2017-2022)
-
Table Cipla Limited Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Product and Service
-
Table Pfizer (Foundation Year, Company Profile and etc.)
-
Table Pfizer Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Sales, Price, Value and Gross Profit (2017-2022)
-
Table Pfizer Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Product and Service
-